Bria-IMT is under clinical development by BriaCell Therapeutics and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bria-IMT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bria-IMT overview
Bria-IMT (BriaVax) is under development for the treatment of advanced metastatic breast cancer, triple-negative breast cancer, HER2+ breast cancer and HER2- breast cancer. The vaccine candidate is administered intradermally. The vaccine candidate is a HER2/neu-positive allogeneic (non-self) breast cancer cell line (SV-BR-1) transfected with the GM-CSF gene to produce the naturally occurring cytokine GM-CSF.
BriaCell Therapeutics overview
BriaCell Therapeutics is an immuno-oncology biotechnology company that focuses on cancer immunotherapy. The company offers pipeline products such as Bria-IMT and Bria-OTS. Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients’ HLA types. It has operations in the US and Canada. BriaCell Therapeutics is headquartered in West Vancouver, British Columbia, Canada.
For a complete picture of Bria-IMT’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
